Details

Autor(en) / Beteiligte

• Tonnus, Wulf
• Meyer, Claudia
• Paliege, Alexander
• Belavgeni, Alexia
• von Mässenhausen, Anne
• Bornstein, Stefan R
• Hugo, Christian
• Becker, Jan Ulrich
• Linkermann, Andreas

Titel

The pathological features of regulated necrosis

Ist Teil von

• The Journal of pathology, 2019-04, Vol.247 (5), p.697-707

Ort / Verlag

Chichester, UK: John Wiley & Sons, Ltd

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• Necrosis of a cell is defined by the loss of its plasma membrane integrity. Morphologically, necrosis occurs in several forms such as coagulative necrosis, colliquative necrosis, caseating necrosis, fibrinoid necrosis, and others. Biochemically, necrosis was demonstrated to represent a number of genetically determined signalling pathways. These include (i) kinase‐mediated necroptosis, which depends on receptor interacting protein kinase 3 (RIPK3)‐mediated phosphorylation of the pseudokinase mixed lineage kinase domain like (MLKL); (ii) gasdermin‐mediated necrosis downstream of inflammasomes, also referred to as pyroptosis; and (iii) an iron‐catalysed mechanism of highly specific lipid peroxidation named ferroptosis. Given the molecular understanding of the nature of these pathways, specific antibodies may allow direct detection of regulated necrosis and correlation with morphological features. Necroptosis can be specifically detected by immunohistochemistry and immunofluorescence employing antibodies to phosphorylated MLKL. Likewise, it is possible to generate cleavage‐specific antibodies against epitopes in gasdermin protein family members. In ferroptosis, however, specific detection requires quantification of oxidative lipids by mass spectrometry (oxylipidomics). Together with classical cell death markers, such as TUNEL staining and detection of cleaved caspase‐3 in apoptotic cells, the extension of the arsenal of necrosis markers will allow pathological detection of specific molecular pathways rather than isolated morphological descriptions. These novel pieces of information will be extraordinarily helpful for clinicians as inhibitors of necroptosis (necrostatins), ferroptosis (ferrostatins), and inflammasomes have emerged in clinical trials. Anatomical pathologists should embrace these novel ancillary tests and the concepts behind them and test their impact on diagnostic precision, prognostication, and the prediction of response to the upcoming anti‐necrotic therapies. Copyright © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.